Your next patient bought their drug of choice at the gas station, right next to the 5-Hour Energy and the rolling papers. They're tachycardic, diaphoretic, vomiting into an emesis bag, and they swear up and down they "don't do drugs." Their urine drug screen is clean. Welcome to kratom withdrawal, and if you can't pronounce mitragynine yet, you're about to.
Kratom encounters are climbing fast, the regulatory landscape is a mess, and most ED docs still aren't putting it on the differential. Let's fix that in ten minutes.
What Kratom Actually Is
Kratom is the ground leaf of Mitragyna speciosa, a Southeast Asian tree in the coffee family. It's sold as powder, capsules, "extracts," and increasingly as concentrated shots and gummies at gas stations, vape shops, and online. In most of the U.S. it's legal, unscheduled, and completely unregulated for purity or dose.
The pharmacology is what matters. The two active alkaloids are mitragynine and 7-hydroxymitragynine. Both are partial mu-opioid receptor agonists, with 7-hydroxymitragynine being substantially more potent than morphine at the mu receptor. Mitragynine also hits alpha-2 adrenergic receptors (think clonidine-ish effects) and has activity at serotonergic and adrenergic sites. At low doses users report a stimulant effect; at higher doses it behaves like an opioid. This is why patients describe it as "natural energy" or "for my back pain" depending on how much they're taking.
The newer wrinkle in 2026 is the proliferation of 7-OH-enriched products, marketed as "extracts" or "shots." These are not your grandmother's herbal tea. They're concentrated semi-synthetic opioids in a wellness wrapper, and they're driving a lot of the dependence we're seeing.
Recognizing Kratom Toxicity
Acute toxicity looks a lot like an opioid overdose with a stimulant veneer. Expect some combination of CNS depression, miosis, respiratory depression, nausea and vomiting, and sometimes seizures. Tachycardia and hypertension can be prominent, especially with co-ingestants or 7-OH products, which can throw you off the opioid scent.
A few clinical pearls worth tattooing on your badge:
Naloxone works, but it's stubborn. Because mitragynine is a partial agonist with a long half-life (around 24 hours) and a large volume of distribution, you may need higher doses or repeated dosing. Don't anchor on "naloxone didn't work, so it's not opioid."
Watch for seizures, QTc prolongation, and hepatotoxicity, especially with chronic heavy use or adulterated products. Case reports of transaminitis and cholestatic injury are well documented. There are also reported associations with intrahepatic cholestasis and, less commonly, cardiac arrest in heavy users.
And critically: your tox screen will not catch this. Mitragynine doesn't cross-react on standard immunoassays. Specialty send-out panels exist, but you're not getting that result during the shift. The diagnosis is clinical and historical, which means you have to actually ask.
Kratom Withdrawal: The One You'll Miss
This is where most of us get burned. A patient comes in looking like classic opioid withdrawal: tachycardic, diaphoretic, mydriatic, yawning, GI distress, anxious, restless. COWS score is 18. UDS negative. They deny opioid use, and they're not lying. They've been taking 15 grams of kratom powder a day for two years and didn't think it counted.
The syndrome is genuinely indistinguishable from opioid withdrawal at the bedside, with maybe a slightly more prominent adrenergic and musculoskeletal component (myalgias, restless legs, irritability). Onset is usually within 12 to 24 hours of last use, peaks around days 2 to 4, and tails off over a week or so, though psychological symptoms can linger.
Two clinical moves that will save you:
-
Ask specifically. "Do you take kratom, krypton, mitragyna, or anything from the gas station for energy or pain?" Generic "any drugs?" gets you nowhere because patients don't categorize it as a drug.
-
Believe the syndrome. If it walks like withdrawal and quacks like withdrawal, treat it like withdrawal, even with a clean screen.
Treatment: Yes, Buprenorphine Works
Here's the punchline that should change your practice: buprenorphine works for kratom withdrawal and kratom use disorder. It's the same pharmacologic logic. Kratom hits mu, buprenorphine is a high-affinity partial mu agonist, and the receptor doesn't care that the patient bought their drug at Shell.
For acute withdrawal in the ED, the standard buprenorphine induction approach applies. Wait for a reasonable COWS (often cited as ≥ 8 to 12, though low-dose induction protocols are increasingly common), then induct. Most patients tolerate this well and feel dramatically better within an hour. Adjunct symptom management with clonidine, ondansetron, loperamide, and NSAIDs rounds out the picture, similar to any opioid withdrawal protocol.
For acute toxicity: supportive care, naloxone if respiratory depression, airway protection as needed, and a low threshold for tox consult, especially with co-ingestants or unusual features. Check an LFT panel and an ECG.
Disposition is where the real medicine happens. Connect them to MAT (medication for addiction treatment) the same way you would any patient with opioid use disorder. Bridge prescriptions, warm handoffs to outpatient buprenorphine clinics, and harm reduction counseling are all on the table. Don't let the "but it's just an herbal supplement" framing make you less aggressive about treatment than you'd be with heroin or oxycodone.
The Regulatory Wild West
Kratom occupies a strange legal limbo. The DEA tried to schedule it in 2016 and backed off after public pushback. The FDA has issued warnings but hasn't banned it. Some states have banned it (Alabama, Arkansas, Indiana, Vermont, Wisconsin), some have passed Kratom Consumer Protection Acts requiring labeling and age limits, and most have done nothing.
The result: wildly variable potency, no purity standards, and the rise of 7-OH-enriched products that are functionally novel synthetic opioids being sold next to the lottery tickets. The FDA has started issuing warning letters about 7-OH products specifically in 2025 and 2026, but enforcement is patchy. Expect to see more of these patients, not fewer.
The Bottom Line
- Ask by name. "Any kratom, gas station shots, or 7-OH products?" Generic drug-use questions miss it every time.
- Trust the syndrome over the screen. UDS does not detect mitragynine. If it looks like opioid withdrawal, treat it like opioid withdrawal.
- Buprenorphine works. Induct in the ED, bridge to outpatient MAT, and treat kratom use disorder with the same seriousness as any OUD.
- Naloxone may need redosing. Long half-life and partial agonism mean the reversal can be sluggish or recur.
- Check LFTs and an ECG in heavy users. Hepatotoxicity and QTc prolongation are real.
Sources
- Patel A, et al. Kratom in the ED: Pearls and Pitfalls. emDocs. https://www.emdocs.net/kratom-in-the-ed-pearls-and-pitfalls/
- FDA. Kratom and 7-Hydroxymitragynine: Warning Letters and Consumer Updates. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- American Kratom Association. Kratom Consumer Protection Act tracker. https://www.americankratom.org/
- Eastlack SC, et al. Kratom: Pharmacology, Clinical Implications, and Outlook. Pain and Therapy. 2020.
- Stanciu CN, et al. Kratom Withdrawal: A Systematic Review. J Subst Abuse Treat. 2019.
Disclaimer: The content on Against Medical Advice — including all podcast episodes, blog posts, and videos — is intended for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Listening to or reading this content does not establish a doctor-patient relationship. Always consult a qualified healthcare provider for medical decisions. The views expressed are those of the hosts and do not represent their employers, residency programs, or affiliated institutions.